ArticleMedicine2026
Influence of metabolic syndrome on disease characteristics and activity in inflammatory bowel disease: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of inflammatory bowel disease (IBD) and metabolic syndrome (MetS) has risen in recent years, but the relationship between the 2 remains understudied. This retrospective cohort study aimed to explore the impact of MetS on disease activity in IBD. Retrospective analysis of 676 consecutive IBD patients treated from January 2023 to April 2024. Study participants were stratified into a control cohort of 531 patients with uncomplicated IBD, and an exposure cohort of 145 patients with IBD and concurrent MetS. Data were collected and analyzed for all 676 patients at baseline and after 1-year follow-up. From an initial pool of 1730 potentially eligible patients, 156 (9%) were identified with MetS (IBD-MetS cohort: 86% ulcerative colitis and 14% Crohn's disease). Baseline clinical disease activity was significantly higher than in the IBD-only controls, with concomitant elevations in biomarkers including monocytosis, eosinophilia, elevated C-reactive protein and elevated erythrocyte sedimentation rate. At 12-months' follow-up, the IBD-MetS group showed significantly lower rates of clinical remission (54.48% vs 82.49%) and mucosal healing (24.83% vs 41.05%) compared to the controls. Inflammatory biomarkers remained elevated, consistent with baseline findings. After propensity score-matched analysis, a comparative analysis of 145 matched controls and 145 exposed groups showed that, compared to IBD-only patients, IBD-MetS patients still had significantly lower rates of clinical remission (54.48% vs 77.93%, odds ratio: 0.339, 95% confidence interval: 0.203-0.565, P < .001) and mucosal healing (24.83% vs 41.38%, odds ratio: 0.468, 95% confidence interval: 0.283-0.772, P = .003). Our findings indicate that MetS is correlated with increased disease activity in IBD. These findings emphasize the need for clinicians to identify and intervene in metabolic syndrome components in IBD patients, ultimately improving quality of life and providing new insights for future IBD-MetS research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.